KalVista Pharmaceuticals (NASDAQ:KALV) Shares Down 7.2% – Should You Sell?

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) shares fell 7.2% during mid-day trading on Monday . The company traded as low as $15.39 and last traded at $15.5860. 281,728 shares traded hands during trading, a decline of 83% from the average session volume of 1,614,548 shares. The stock had previously closed at $16.80.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a research report on Wednesday, October 8th. HC Wainwright increased their price objective on shares of KalVista Pharmaceuticals from $27.00 to $37.00 and gave the company a “buy” rating in a research note on Friday, January 9th. Cowen reaffirmed a “buy” rating on shares of KalVista Pharmaceuticals in a research report on Wednesday, December 3rd. Wall Street Zen upgraded KalVista Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, December 6th. Finally, Needham & Company LLC upped their price objective on KalVista Pharmaceuticals from $28.00 to $32.00 and gave the company a “buy” rating in a research note on Tuesday, January 6th. Eight research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, KalVista Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $29.17.

KalVista Pharmaceuticals Trading Up 2.0%

The company has a debt-to-equity ratio of 8.18, a current ratio of 7.22 and a quick ratio of 7.21. The firm has a fifty day simple moving average of $14.85 and a two-hundred day simple moving average of $13.68. The firm has a market capitalization of $770.32 million, a P/E ratio of -3.86 and a beta of -0.14.

KalVista Pharmaceuticals (NASDAQ:KALV) last issued its quarterly earnings results on Monday, November 10th. The specialty pharmaceutical company reported ($0.92) EPS for the quarter, beating analysts’ consensus estimates of ($0.96) by $0.04. The firm had revenue of $13.69 million for the quarter, compared to analysts’ expectations of $6.03 million. On average, equities research analysts anticipate that KalVista Pharmaceuticals, Inc. will post -3.56 earnings per share for the current fiscal year.

Insider Transactions at KalVista Pharmaceuticals

In related news, insider Paul K. Audhya sold 5,296 shares of the company’s stock in a transaction that occurred on Monday, November 24th. The shares were sold at an average price of $13.45, for a total transaction of $71,231.20. Following the sale, the insider directly owned 131,831 shares in the company, valued at approximately $1,773,126.95. This represents a 3.86% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO Brian Piekos sold 4,471 shares of the firm’s stock in a transaction on Monday, November 24th. The stock was sold at an average price of $13.45, for a total value of $60,134.95. Following the completion of the transaction, the chief financial officer directly owned 10,529 shares of the company’s stock, valued at $141,615.05. The trade was a 29.81% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 31,329 shares of company stock worth $437,371 over the last quarter. Corporate insiders own 4.30% of the company’s stock.

Institutional Trading of KalVista Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of KALV. Tudor Investment Corp ET AL purchased a new position in shares of KalVista Pharmaceuticals during the 3rd quarter valued at $24,360,000. Parkman Healthcare Partners LLC boosted its stake in KalVista Pharmaceuticals by 155.5% during the third quarter. Parkman Healthcare Partners LLC now owns 1,735,003 shares of the specialty pharmaceutical company’s stock valued at $21,132,000 after buying an additional 1,055,940 shares during the period. Ameriprise Financial Inc. boosted its stake in KalVista Pharmaceuticals by 2,258.6% during the second quarter. Ameriprise Financial Inc. now owns 945,125 shares of the specialty pharmaceutical company’s stock valued at $10,685,000 after buying an additional 905,053 shares during the period. Freestone Grove Partners LP purchased a new position in KalVista Pharmaceuticals during the third quarter worth about $8,580,000. Finally, Schroder Investment Management Group grew its position in KalVista Pharmaceuticals by 108.7% during the third quarter. Schroder Investment Management Group now owns 1,158,457 shares of the specialty pharmaceutical company’s stock worth $14,145,000 after buying an additional 603,499 shares in the last quarter.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.